Cogent Biosciences, Inc.
Cogent Biosciences, Inc. (COGT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · COGT · as of Sep 30, 2025
Ownership Breakdown
202
Institutional Holders
▲ 9 vs Q2
$2.29B
Total Inst. Value
▲ $1.31B vs Q2
170.87M
Shares Outstanding
freeFloat 86.08%
159.23M
13F Shares Held
▲ 23.69M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
COGT largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
FMR LLC pharmaceutical preparations | 22.41M | 19.58% | 19.58% | $321.78B | Nov 13, 2025 | ▲ 5.33M |
BLACKROCK, INC. pharmaceutical preparations | 10.37M | 9.06% | 9.06% | $148.91B | Nov 12, 2025 | ▲ 1.74M |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) pharmaceutical preparations | 9.05M | 7.91% | 7.91% | $130.00B | Nov 14, 2025 | ▲ 6.41M |
FAIRMOUNT FUNDS MANAGEMENT LLC pharmaceutical preparations | 9.00M | 7.87% | 7.87% | $129.29B | Nov 14, 2025 | ▲ 2.78M |
KYNAM CAPITAL MANAGEMENT, LP pharmaceutical preparations | 7.89M | 6.89% | 6.89% | $113.25B | Nov 14, 2025 | ▼ 606.4K |
VANGUARD GROUP INC pharmaceutical preparations | 7.76M | 6.78% | 6.78% | $111.40B | Nov 7, 2025 | ▲ 1.23M |
COMMODORE CAPITAL LP pharmaceutical preparations | 7.25M | 6.33% | 6.33% | $104.11B | Nov 14, 2025 | ▲ 4.94M |
TCG CROSSOVER MANAGEMENT, LLC pharmaceutical preparations | 6.80M | 5.94% | 5.94% | $97.62B | Nov 17, 2025 | ▼ 166.2K |
STATE STREET CORP pharmaceutical preparations | 4.78M | 4.17% | 4.17% | $68.58B | Nov 14, 2025 | ▲ 1.40M |
VR ADVISER, LLC pharmaceutical preparations | 4.00M | 3.49% | 3.49% | $57.44B | Nov 14, 2025 | ▼ 755.4K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
31
Increased
+37.91M shares7
New Positions
first time holders12
Decreased
−15.84M shares0
Sold Out
fully exitedNet shares change (top 50)
+22.07M
+37.91M / −15.84M
Net new holders
+26
7 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
COGT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
1
Sell transactions
2.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Robbins Andrew R President and CEO | May 19, 2026 | Gift | 160,000 | — | — | 497.5K | Form 4 ↗ |
Robbins Andrew R President and CEO | May 19, 2026 | Gift | 160,000 | — | — | 160.0K | Form 4 ↗ |
Ferrante Karen Jean director | Apr 1, 2026 | Award | 686 | $35.24 | $24.2K | 686 | Form 4 ↗ |
Fairmount Funds Management LLC director | Mar 31, 2026 | C-Conversion | 7,000,000 | — | — | 12.50M | Form 4 ↗ |
Fairmount Funds Management LLC director | Mar 31, 2026 | Sale | 7,000,000 | $34.66 | $242.62M | 5.50M | Form 4 ↗ |
Fairmount Funds Management LLC director | Mar 31, 2026 | C-Conversion | 28,000 | — | — | 39.4K | Form 4 ↗ |
Fairmount Funds Management LLC director | Jan 22, 2026 | Sale | 3,500,000 | $36.40 | $127.40M | 5.50M | Form 4 ↗ |
Ferrante Karen Jean director | Jan 1, 2026 | Award | 643 | $34.74 | $22.3K | 643 | Form 4 ↗ |
Kearns Evan Chief Legal Officer | Dec 26, 2025 | Sale | 65,000 | $38.70 | $2.52M | 109.4K | Form 4 ↗ |
Green John L. Chief Financial Officer | Dec 26, 2025 | Sale | 77,000 | $38.68 | $2.98M | 131.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Cogent Biosciences, Inc. (COGT) is primarily owned by institutional investors, who hold approximately 93.2% of total shares outstanding. Company insiders own approximately 13.92%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Cogent Biosciences, Inc. is FMR LLC, holding approximately 22.41 million shares — equal to 19.58% of outstanding shares — as of September 30, 2025.
A total of 202 institutional investors currently hold COGT stock, with a combined institutional value of approximately $2.29 billion as of the most recent 13F filing period.
Frequently asked questions
COGT ownershipCogent Biosciences, Inc. (COGT) is primarily owned by institutional investors, who hold approximately 93.2% of shares. The largest shareholder is FMR LLC with a 19.58% stake. Company insiders hold 13.92%. Data sourced from SEC Form 13F as of September 30, 2025.